LAS VEGAS--(BUSINESS WIRE)--April 26, 2006--CardioVascular BioTherapeutics, Inc. (OTCBB:CVBT - News) today announced that it has signed a collaborative research and development agreement with the global clinical contract research organization, bioRASI, to initiate proof of concept clinical studies in patients suffering from chronic back pain. Chronic back pain, estimated in published reports to affect 26 million Americans, has recently been linked to blockage of blood vessels supplying the lower back, leading to a condition referred to as lumbar ischemia. The patients will receive CVBT’s new drug candidate for lumbar ischemia which has Cardio Vascu-Grow(TM) as its active ingredient. The multi-site clinical study will be performed in Russia and Eastern Europe and will enroll patients who have proven blockages in their lumbar arteries which leads to poor perfusion and chronic pain in their lower backs.
